New Found Gold’s Revised Queensway PEA Lifts After Tax NPV to C$1.73 Billion

Revised Queensway PEA Lifts After Tax NPV to C$1.73 Billion

New Found Gold (TSX: NFGC) has more than doubled the projected value of its Queensway gold project in Newfoundland, releasing a revised preliminary economic assessment that pegs the project’s after-tax net present value at C$1.73 billion. The figure, calculated at a 5% discount rate, comes with an after-tax internal rate of return of 126% and […]

Newmont Posts $2.20 Adjusted EPS as Q3 AISC Drops to US$1,454 per Ounce

Posts $2.20 Adjusted EPS as Q3 AISC Drops to US$1,454 per Ounce

Newmont Corporation (NYSE: NEM) lowered its 2026 cost guidance on Thursday after a third quarter in which a recovering Cadia operation and stronger co-product volumes pulled unit costs well below the prior period. Revenue for the three months ended September 30 came in at $6.36 billion, up from $6.12 billion in the second quarter, as […]

Integra Lifts Florida Canyon Gold Output 8% to 17,652 Ounces in Third Quarter

Lifts Florida Canyon Gold Output 8% to 17,652 Ounces in Third Quarter

Integra Resources (TSXV: ITR) produced 17,652 ounces of gold at its Florida Canyon Mine in Nevada during the third quarter, an 8% increase from the second quarter and 40% above the first quarter of the year. Gold sales came in at 16,760 ounces. Most of the gain came from volume. Ore mined rose 21% quarter […]

Boroo Strikes C$140 Million Deal for Victoria Gold, Eagle Mine Restart in Sight

Boroo Strikes C$140 Million Deal for Victoria Gold, Eagle Mine Restart in Sight

Boroo Pte. Ltd. has agreed to acquire Victoria Gold out of receivership, putting the idled Eagle gold mine in Yukon on a path back to production more than two years after a heap leach failure forced it to shut down. Under a subscription agreement with PricewaterhouseCoopers, the court appointed receiver, Boroo subsidiary Gatsuurt Mining Inc. […]

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Roche’s $813 Million Zymeworks Deal Adds to $1.08 Billion Cancer Bet

Months before Vancouver-based Zymeworks agreed to license its experimental cancer treatment to Roche, the biotechnology company had already identified two Roche-linked drugs among its potential competitors. The disclosure, contained in Zymeworks’ March 2026 annual filing, places Friday’s $813 million agreement within a broader Roche investment in treatments targeting DLL3, a protein associated with small-cell lung […]

Johnson & Johnson and Smith & Nephew Merger: $10 Billion Debt and “Who Would Be CEO” Dispute

A proposed $34 billion merger between Johnson & Johnson’s orthopaedics business and Smith & Nephew would have involved approximately $10 billion in debt financing from the British medical-device maker while giving J&J shareholders 50.1% of the combined company, according to the Financial Times. The financing component was more than three times Smith & Nephew’s $3.02 billion in net debt as of June 27, 2026. Under the terms described by the outlet, the borrowing would have funded a roughly $10 billion payment to J&J, helping reconcile the businesses’ differing valuations. J&J’s orthopaedics operation was valued at up to $22 billion, compared with Smith & Nephew’s market capitalization of approximately $12.6 billion cited in the reporting. Smith & Nephew’s latest published results show the financial scale involved. At the end of the first half, the company reported a net-debt-to-adjusted-EBITDA ratio of 1.8 times and free cash flow of $231 million, down from $244 million a year earlier. In August, it maintained its full-year free cash flow forecast of approximately $800 million while reducing expected underlying revenue growth to around 4% from around 6%. The proposed $10 billion borrowing was equivalent to 12.5 times that standalone annual cash flow forecast, before accounting for earnings, borrowing costs, or other financial effects of a combined business. Leadership stopped the talks Despite reported agreement on the transaction’s principal economics, the merger discussions broke down over management. The FT reported, citing people familiar with the negotiations, that J&J wanted DePuy Synthes president Namal Nawana to lead the combined company. Smith & Nephew chairman Rupert Soames instead insisted that incumbent chief executive Deepak Nath retain the position, according to the report. Nawana previously served as Smith & Nephew’s CEO, departing in 2019 amid a compensation disagreement. J&J had publicly designated Nawana as the expected leader of DePuy Synthes when it announced plans to separate the orthopaedics business in October 2025. The division generated $9.3 billion in sales in 2025, according to J&J’s financial results. On October 13, J&J CEO Joaquin Duato said the company was leaning toward spinning off DePuy Synthes as a standalone company, with separation targeted for mid-2027.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines